Lipella Pharmaceuticals revenue was $536.36k for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $173.7k, up 116.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LIPO annual revenue was $536.4k, with 19.3% growth year-over-year.
LIPO past revenue growth
How has LIPO's revenue growth performed historically?
Lipella Pharmaceuticals (NASDAQ: LIPO) reported Q4 2024 revenue of $173.67 thousand up 43.71% year over year. In the same quarter last year, Lipella Pharmaceuticals's revenue was $120.84 thousand.
What was Lipella Pharmaceuticals's revenue in 2024?
Lipella Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $536.36 thousand, a 19.29% increase year over year.
How much does Lipella Pharmaceuticals make in a day?
Based on Lipella Pharmaceuticals annual revenue for the past four years, LIPO makes an average of $979.09 per day.
What was Lipella Pharmaceuticals's annual revenue growth in the past year?
As of Q2 2025, Lipella Pharmaceuticals's revenue has grown 19.29% year over year. This is 478.4 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Lipella Pharmaceuticals's revenue in the past year totaled $536.36 thousand.
How much does Lipella Pharmaceuticals make in a year?
Lipella Pharmaceuticals's revenue by year for the past four years is:
Lipella Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $536.36 thousand, a 19.29% increase year over year.
Lipella Pharmaceuticals's annual revenue for Dec 31, 2023 was $449.62 thousand, a 144.15% increase from 2022.
Lipella Pharmaceuticals's annual revenue for 2022 was $184.16 thousand, a 28.99% decrease from 2021.
Lipella Pharmaceuticals's annual revenue for 2021 was $259.35 thousand, a 73.03% decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.